AIM
AIM ImmunoTech·AMEX
--
--(--)
--
--(--)
3.63 / 10
Netural
Liquidity flow is relatively robust at 7.27/10, with optimistic Small and Extra-large inflow trends, despite a negative overall flow direction. Analyst coverage is minimal but overwhelmingly bullish (Strong Buy 100%), though historical win rates are low (0.0%). This divergence between positive fund flow and negative analyst track record warrants vigilance.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-12-08
InstitutionAscendiant Capital
Times predicted2
Historical Win Rate0.0%
Is money flowing into or out of AIM?
- AIM holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 3.63/10 (Netural).
